UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 10, 2025
PDS BIOTECHNOLOGY CORPORATION
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
001-37568
|
26-4231384
|
| |
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
303A College Road East, Princeton, NJ 08540
(Address of Principal Executive Offices, and Zip Code)
(800) 208-3343
Registrant’s Telephone Number, Including Area Code
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| ☐ |
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
Common Stock, par value $0.00033 per share
|
PDSB
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐
On November 10, 2025, PDS Biotechnology Corporation issued a press release announcing positive clinical and translational data
presented at the 2025 Society for Immunotherapy of Cancer Annual Meeting. The presentations highlight immune-driven mechanisms and biomarkers that explain strong clinical
activity of the Company’s investigational HPV16-targeted immunotherapy PDS0101 and its novel, investigational immunocytokine PDS01ADC.
A copy of the press release is filed herewith as Exhibit 99.1 and incorporated by reference herein.
| Item 9.01 |
Financial Statements and Exhibits.
|
|
Exhibit
Number
|
|
Description
|
| |
|
|
|
99.1
|
|
Press Release Dated November 10, 2025.
|
| |
|
|
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL Document).
|
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
| |
PDS BIOTECHNOLOGY CORPORATION
|
| |
|
|
Date: November 10, 2025
|
By:
|
/s/ Frank Bedu-Addo, Ph.D.
|
| |
Name: Frank Bedu-Addo, Ph.D.
|
| |
Title: President and Chief Executive Officer
|
